Clinical trials: Solid Organ Transplantation Recipient

Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus

Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

• Recruiting
• Age: 1 year to 85 years
• Early Phase 1
• Injection or infusion

This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus [CMV] specific cytotoxic T-lymphocytes [CTLs]) or allogeneic adenovirus-specific cytotoxic T…

Conditions

Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus, Donor, Solid Organ Transplantation Recipient

Trial name

NCT03665675

Testing

Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes, Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes

Where

2 sites in United States

Volunteers

20 people, healthy volunteers welcome

Sponsor

Sumithira Vasu